A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 267 participants.
Also called NCT04992065
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 267 participants
- Sponsor
- Registry
-
NCT04992065 -
2020-002630-32
-
- Main results
- PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Germany, Greece, Japan, Netherlands, Poland
- Registry status
- Completed
Technical summary
Registry record NCT04992065. Randomized; double masking; primary purpose treatment. Start 2021-08-03 (actual); primary completion 2022-04-26 (actual). Results posted on 2025-06-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study Looking at How NNC0385-0434 Tablets Work to Lower Blood Cholesterol in People With Heart Disease or a High Risk of Heart Disease
- Condition
- Atherosclerotic Cardiovascular Disease
- Intervention (Drug)
- NNC0385-0434 A 15 mg
- Intervention (Drug)
- NNC0385-0434 A 40 mg
- Intervention (Other)
- Placebo I A (for NNC0385-0434 A 15 mg)
- Intervention (Drug)
- NNC0385-0434 A 100 mg
- Intervention (Other)
- Placebo I A (for NNC0385-0434 A 40 mg)
- Intervention (Other)
- Placebo II A (for NNC0385-0434 A 100 mg)
- Intervention (Drug)
- Evolocumab 140 mg/mL, Repatha®
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct04992065- Content hash
360a8072195007b79604717e6f877d841dd8a88b952a22ae568865f727e36185